We read with interest the article by Rogers and colleagues titled “Prospective Randomized Trial of LC + LCBDE vs ERCP/S + LC for Common Bile Duct Stone Disease.”1 The authors are to be commended for undertaking and reporting on a randomized study in an area in which clinical practice in selecting between these 2 therapeutic options is currently largely dictated by institutional expertise and individual physician preference, as opposed to outcome data from controlled studies.